US 12,325,748 B2
Bifunctional fusion protein against PDL1 and TGFβ and use thereof
Deyong Song, Yantai (CN); Hongguang Xu, Yantai (CN); and Zhen Han, Yantai (CN)
Assigned to Shandong Boan Biotechnology Co., Ltd., Yantai (CN)
Appl. No. 17/601,891
Filed by Shandong Boan Biotechnology Co., Ltd., Yantai (CN)
PCT Filed Jun. 8, 2020, PCT No. PCT/CN2020/094855
§ 371(c)(1), (2) Date Oct. 6, 2021,
PCT Pub. No. WO2020/248926, PCT Pub. Date Dec. 17, 2020.
Claims priority of application No. 201910497064.X (CN), filed on Jun. 10, 2019; and application No. 201910497723.X (CN), filed on Jun. 10, 2019.
Prior Publication US 2022/0213195 A1, Jul. 7, 2022
Int. Cl. C07K 16/28 (2006.01); A61P 35/00 (2006.01); C07K 14/71 (2006.01); C12N 15/85 (2006.01); A61K 39/00 (2006.01)
CPC C07K 16/2827 (2013.01) [A61P 35/00 (2018.01); C07K 14/71 (2013.01); C12N 15/85 (2013.01); A61K 2039/505 (2013.01); C07K 2317/31 (2013.01); C07K 2317/622 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01); C07K 2319/32 (2013.01)] 6 Claims
 
1. An antibody or antigen-binding fragment thereof, comprising (1) three heavy chain complementarity determining regions (HCDR1, HCDR2 and HCDR3), wherein HCDR1 comprises SEQ ID NO: 8, HCDR2 comprises SEQ ID NO: 9, and HCDR3 comprises SEQ ID NO: 10 and (2) three light chain complementarity determining regions (LCDR1, LCDR2 and LCDR3), wherein LCDR1 comprises SEQ ID NO: 5, LCDR2 comprises SEQ ID NO: 6, and LCDR3 comprises SEQ ID NO: 7, wherein the antibody or antigen-binding fragment thereof binds to PDL1.